Streetbeat News

Regulatory

CODX

Co-Diagnostics, Inc. (CODX) announced the appointment of Richard Abbott as President and David Nielsen as COO, along with other key executive roles. These appointments are part of the company's strategy to advance and commercialize its Co-Dx PCR platform and associated tests. The Co-Dx PCR platform is under FDA review and not yet available for sale. The company aims to fill the diagnostics access gap with its technology.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:31 pm

ABAT

American Battery Technology Company (ABTC) has been awarded an additional $40.5M tax credit by the U.S. Department of Treasury to accelerate the construction of a new lithium-ion battery recycling facility in the U.S. This award, part of the Qualifying Advanced Energy Project Credits program, supplements a previous $20M credit and aims to expand North America's closed-loop battery metals supply chain. ABTC is engaging with major automotive OEMs and battery cell manufacturers for recycling services and is planning the new facility to increase domestic critical battery minerals manufacturing capacity.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:26 pm

TLRY

Tilray Brands Inc (NASDAQ:TLRY) shares have surged nearly 75% over the last month, driven by cannabis legalization in Germany, optimism for U.S. rescheduling, and a favorable Florida Supreme Court decision. The company announced new products and 420 celebratory events in Canada, and is set to report Q3 financial results with an expected loss of 5 cents per share and revenue of $198.62 million.

Portfolio Pulse from Adam Eckert

April 04, 2024 | 1:24 pm

AAPL

NVDA

TSLA

The article covers a range of topics from cryptocurrency trends, including Bitcoin's potential surge, to tech updates like iPhone 16 rumors and Tesla's EV developments. It also touches on US and world politics, market movements, and company-specific news such as Apple's stock sale by CEO Tim Cook and Nvidia's supplier investment in the US chip sector.

Portfolio Pulse from Akanksha Bakshi

April 04, 2024 | 1:11 pm

COIN

Coinbase shares are trading higher following the news that the company has been granted a registration license in Canada. Additionally, the increase in the stock price may be attributed to a rise in Bitcoin value.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 1:06 pm

AXNX

BSX

Axonics (AXNX) and Boston Scientific (BSX) shares are trading lower after receiving a request for additional information from the FTC regarding their merger agreement. The completion of the merger is now anticipated in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:57 pm

AXNX

BSX

Boston Scientific and Axonics received a request for additional information from the FTC regarding their merger review, delaying the expected completion to the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:55 pm

ETH-USD

VanEck predicts Ethereum Layer 2 networks will surpass a $1 trillion valuation by 2030, based on an evaluation of 46 L2 networks. Currently, Arbitrum leads with $18 billion in locked tokens. Despite potential growth, VanEck remains bearish on many networks due to competition and risks like an oversupply of L2 tokens.

Portfolio Pulse from Benzinga Neuro

April 04, 2024 | 12:54 pm

UMC

United Microelectronics (UMC) announced in an SEC filing that operations and wafer shipments have resumed normally with no significant impact on its finances or business following a recent earthquake in Taiwan.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:41 pm

SLP

Simulations Plus, Inc. (NASDAQ:SLP) announced the U.S. FDA has renewed its licenses for the DILIsym software platform for the 7th consecutive year. DILIsym is a leading quantitative systems toxicology software used to predict and investigate drug-induced liver injury (DILI), supporting the FDA's drug evaluation and approval process. The renewal allows FDA employees across all divisions continued access to DILIsym. The software plays a crucial role in understanding DILI risk in new molecules and tailoring dosing strategies for safety and efficacy. Simulations Plus has led the DILI-sim Initiative for 14 years, a public-private partnership guiding DILIsym's development.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:36 pm